Literature DB >> 2922387

An ultrastructural and immunohistochemical evaluation of cytodifferentiation in neuroblastic tumors.

Y Hachitanda1, M Tsuneyoshi, M Enjoji.   

Abstract

Twenty-six cases of neurogenic tumors consisting of 2 ganglioneuromas (GN), 8 ganglioneuroblastomas (GNB), and 16 neuroblastomas (NB) were studied to evaluate their cytodifferentiation. Ultrastructurally, a moderate to large number of neuritic processes and high density neurosecretory granules (NSG) were found in all cases of GN and well-differentiated GNB, in two-thirds of poorly differentiated GNB, in about a half of rosette-fibrillary NB, and in no case of round-cell NB. All GN and GNB had tumor cells which were positive for both chromogranin and neurofilaments. Of the 16 cases of NB, 12 were positive for chromogranin, and 13 and 15 were positive for Mr 200,000 and 68,000 neurofilament polypeptides, respectively. However, both markers appeared mainly in tumor cells maturing toward neuroblasts. Electron microscopy was helpful for the diagnosis of undifferentiated NB in those cases immunohistochemically negative for chromogranin or neurofilaments. We conclude that ultrastructural and immunohistochemical examinations are useful for the morphologic assessment of the degree of maturation of neuroblastic tumors.

Entities:  

Mesh:

Year:  1989        PMID: 2922387

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  2 in total

1.  Distinct morphological and immunohistochemical features and different growth rates among four human neuroblastomas heterotransplanted into nude mice.

Authors:  Nobuo Hoshi; Jiro Hitomi; Takashi Kusakabe; Takeaki Fukuda; Masayuki Hirota; Toshimitsu Suzuki
Journal:  Med Mol Morphol       Date:  2008-09-20       Impact factor: 2.309

2.  Neuroblastoma Soft Tissue Metastasis in a 10-Month-Old Infant with a Right Thigh Mass.

Authors:  Shokouh Taghipour Zahir; Fateme Salemi
Journal:  Case Rep Med       Date:  2021-09-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.